HIV Treatment Drugs Market in Africa 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	162 Pages	TechNavio	July, 2024	INF19115306

Best Price Guarantee
Price	from $2,500
Length	162 Pages
Publisher	TechNavio
Published Date	July, 2024
SKU	INF19115306

HIV Treatment Drugs Market in Africa 2024-2028

Global Hiv Treatment Drugs Market In Africa 2024-2028

The hiv treatment drugs market in africa is forecasted to grow by USD 280.2 mn during 2023-2028, accelerating at a CAGR of 3.2% during the forecast period. The report on the hiv treatment drugs market in africa provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of stds, favorable international programs, and government collaborations.

Technavio's hiv treatment drugs market in africa is segmented as below:

By Drug Class
Reverse transcriptase inhibitors
Protease inhibitors
Integrase inhibitors
Fusion inhibitors
Coreceptor antagonists
By Route Of Administration
Oral drugs
Injectable drugs
By Geographical Landscape
Africa

This study identifies the increase in awareness by various organizations as one of the prime reasons driving the hiv treatment drugs market in africa growth during the next few years. Also, growing focus on elimination of mother-to-child transmission of hiv and high hiv drug resistance will lead to sizable demand in the market.

The report on the hiv treatment drugs market in africa covers the following areas:

Hiv treatment drugs market in africa sizing
Hiv treatment drugs market in africa forecast
Hiv treatment drugs market in africa industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hiv treatment drugs market in africa vendors that include Abbott Laboratories, AbbVie Inc., Alpha Pharma, Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Avacare Health, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Merck and Co. Inc., SSI Diagnostica AS, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Theratechnologies Inc., and Viatris Inc.. Also, the hiv treatment drugs market in africa analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Country Market Characteristics; Executive Summary - Chart on Market By Geographical Landscape; Executive Summary - Chart on Market Segmentation by Drug Class; Executive Summary - Chart on Market Segmentation by Route of Administration; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 2.2 Market characteristics; Market characteristics analysis; 2.3 Value chain analysis; Value Chain Analysis
3 Market Sizing: 3.1 Market definition; Offerings of companies included in the market definition; 3.2 Market segment analysis; Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Chart on Africa - Market size and forecast 2023-2028 ($ million); Data Table on Regional - Market size and forecast 2023-2028 ($ million); Chart on Africa: Year-over-year growth 2023-2028 (%); Data Table on Regional - Market size and forecast 2023-2028 ($ million)
4 Historic Market Size: 4.1 HIV Treatment Drugs Market in Africa 2018 - 2022; Historic Market Size - Data Table on HIV Treatment Drugs Market in Africa 2018 - 2022 ($ million); 4.2 Drug Class segment analysis 2018 - 2022; Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); 4.3 Route of Administration segment analysis 2018 - 2022; Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million); 4.4 Geography segment analysis 2018 - 2022; Historic Market Size - Geography Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Drug Class: 6.1 Market segments; Chart on Drug Class - Market share 2023-2028 (%); Data Table on Drug Class - Market share 2023-2028 (%); 6.2 Comparison by Drug Class; Chart on Comparison by Drug Class; Data Table on Comparison by Drug Class; 6.3 Reverse transcriptase inhibitors - Market size and forecast 2023-2028; Chart on Reverse transcriptase inhibitors - Market size and forecast 2023-2028 ($ million); Data Table on Reverse transcriptase inhibitors - Market size and forecast 2023-2028 ($ million); Chart on Reverse transcriptase inhibitors - Year-over-year growth 2023-2028 (%); Data Table on Reverse transcriptase inhibitors - Year-over-year growth 2023-2028 (%); 6.4 Protease inhibitors - Market size and forecast 2023-2028; Chart on Protease inhibitors - Market size and forecast 2023-2028 ($ million); Data Table on Protease inhibitors - Market size and forecast 2023-2028 ($ million); Chart on Protease inhibitors - Year-over-year growth 2023-2028 (%); Data Table on Protease inhibitors - Year-over-year growth 2023-2028 (%); 6.5 Integrase inhibitors - Market size and forecast 2023-2028; Chart on Integrase inhibitors - Market size and forecast 2023-2028 ($ million); Data Table on Integrase inhibitors - Market size and forecast 2023-2028 ($ million); Chart on Integrase inhibitors - Year-over-year growth 2023-2028 (%); Data Table on Integrase inhibitors - Year-over-year growth 2023-2028 (%); 6.6 Fusion inhibitors - Market size and forecast 2023-2028; Chart on Fusion inhibitors - Market size and forecast 2023-2028 ($ million); Data Table on Fusion inhibitors - Market size and forecast 2023-2028 ($ million); Chart on Fusion inhibitors - Year-over-year growth 2023-2028 (%); Data Table on Fusion inhibitors - Year-over-year growth 2023-2028 (%); 6.7 Coreceptor antagonists - Market size and forecast 2023-2028; Chart on Coreceptor antagonists - Market size and forecast 2023-2028 ($ million); Data Table on Coreceptor antagonists - Market size and forecast 2023-2028 ($ million); Chart on Coreceptor antagonists - Year-over-year growth 2023-2028 (%); Data Table on Coreceptor antagonists - Year-over-year growth 2023-2028 (%); 6.8 Market opportunity by Drug Class; Market opportunity by Drug Class ($ million); Data Table on Market opportunity by Drug Class ($ million)
7 Market Segmentation by Route of Administration: 7.1 Market segments; Chart on Route of Administration - Market share 2023-2028 (%); Data Table on Route of Administration - Market share 2023-2028 (%); 7.2 Comparison by Route of Administration; Chart on Comparison by Route of Administration; Data Table on Comparison by Route of Administration; 7.3 Oral drugs - Market size and forecast 2023-2028; Chart on Oral drugs - Market size and forecast 2023-2028 ($ million); Data Table on Oral drugs - Market size and forecast 2023-2028 ($ million); Chart on Oral drugs - Year-over-year growth 2023-2028 (%); Data Table on Oral drugs - Year-over-year growth 2023-2028 (%); 7.4 Injectable drugs - Market size and forecast 2023-2028; Chart on Injectable drugs - Market size and forecast 2023-2028 ($ million); Data Table on Injectable drugs - Market size and forecast 2023-2028 ($ million); Chart on Injectable drugs - Year-over-year growth 2023-2028 (%); Data Table on Injectable drugs - Year-over-year growth 2023-2028 (%); 7.5 Market opportunity by Route of Administration; Market opportunity by Route of Administration ($ million); Data Table on Market opportunity by Route of Administration ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Chart on Market share By Geographical Landscape - 2023-2028 (%); Data Table on Market share By Geographical Landscape - 2023-2028 (%); 9.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 9.3 South Africa - Market size and forecast 2023-2028; Chart on South Africa - Market size and forecast 2023-2028 ($ million); Data Table on South Africa - Market size and forecast 2023-2028 ($ million); Chart on South Africa - Year-over-year growth 2023-2028 (%); Data Table on South Africa - Year-over-year growth 2023-2028 (%); 9.4 Nigeria - Market size and forecast 2023-2028; Chart on Nigeria - Market size and forecast 2023-2028 ($ million); Data Table on Nigeria - Market size and forecast 2023-2028 ($ million); Chart on Nigeria - Year-over-year growth 2023-2028 (%); Data Table on Nigeria - Year-over-year growth 2023-2028 (%); 9.5 Kenya - Market size and forecast 2023-2028; Chart on Kenya - Market size and forecast 2023-2028 ($ million); Data Table on Kenya - Market size and forecast 2023-2028 ($ million); Chart on Kenya - Year-over-year growth 2023-2028 (%); Data Table on Kenya - Year-over-year growth 2023-2028 (%); 9.6 Uganda - Market size and forecast 2023-2028; Chart on Uganda - Market size and forecast 2023-2028 ($ million); Data Table on Uganda - Market size and forecast 2023-2028 ($ million); Chart on Uganda - Year-over-year growth 2023-2028 (%); Data Table on Uganda - Year-over-year growth 2023-2028 (%); 9.7 Rest of Africa - Market size and forecast 2023-2028; Chart on Rest of Africa - Market size and forecast 2023-2028 ($ million); Data Table on Rest of Africa - Market size and forecast 2023-2028 ($ million); Chart on Rest of Africa - Year-over-year growth 2023-2028 (%); Data Table on Rest of Africa - Year-over-year growth 2023-2028 (%); 9.8 Market opportunity By Geographical Landscape; Market opportunity By Geographical Landscape ($ million); Data Table on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Opportunity/Restraints: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Impact of drivers and challenges in 2023 and 2028; 10.4 Market opportunities/restraints
11 Competitive Landscape: 11.1 Overview; 11.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 11.3 Landscape disruption; Overview on factors of disruption; 11.4 Industry risks; Impact of key risks on business
12 Competitive Analysis: 12.1 Companies profiled; Companies covered; 12.2 Market positioning of companies; Matrix on companies position and classification; 12.3 Abbott Laboratories; Abbott Laboratories - Overview; Abbott Laboratories - Business segments; Abbott Laboratories - Key news; Abbott Laboratories - Key offerings; Abbott Laboratories - Segment focus; 12.4 AbbVie Inc.; AbbVie Inc. - Overview; AbbVie Inc. - Product / Service; AbbVie Inc. - Key news; AbbVie Inc. - Key offerings; 12.5 Alpha Pharma; Alpha Pharma - Overview; Alpha Pharma - Product / Service; Alpha Pharma - Key offerings; 12.6 Aspen Pharmacare Holdings Ltd.; Aspen Pharmacare Holdings Ltd. - Overview; Aspen Pharmacare Holdings Ltd. - Business segments; Aspen Pharmacare Holdings Ltd. - Key offerings; Aspen Pharmacare Holdings Ltd. - Segment focus; 12.7 AstraZeneca Plc; AstraZeneca Plc - Overview; AstraZeneca Plc - Product / Service; AstraZeneca Plc - Key news; AstraZeneca Plc - Key offerings; 12.8 Aurobindo Pharma Ltd.; Aurobindo Pharma Ltd. - Overview; Aurobindo Pharma Ltd. - Product / Service; Aurobindo Pharma Ltd. - Key offerings; 12.9 Avacare Health; Avacare Health - Overview; Avacare Health - Product / Service; Avacare Health - Key offerings; 12.10 Cipla Inc.; Cipla Inc. - Overview; Cipla Inc. - Business segments; Cipla Inc. - Key news; Cipla Inc. - Key offerings; Cipla Inc. - Segment focus; 12.11 F. Hoffmann La Roche Ltd.; F. Hoffmann La Roche Ltd. - Overview; F. Hoffmann La Roche Ltd. - Business segments; F. Hoffmann La Roche Ltd. - Key news; F. Hoffmann La Roche Ltd. - Key offerings; F. Hoffmann La Roche Ltd. - Segment focus; 12.12 Gilead Sciences Inc.; Gilead Sciences Inc. - Overview; Gilead Sciences Inc. - Product / Service; Gilead Sciences Inc. - Key news; Gilead Sciences Inc. - Key offerings; 12.13 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; 12.14 Merck and Co. Inc.; Merck and Co. Inc. - Overview; Merck and Co. Inc. - Business segments; Merck and Co. Inc. - Key news; Merck and Co. Inc. - Key offerings; Merck and Co. Inc. - Segment focus; 12.15 Sun Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd. - Overview; Sun Pharmaceutical Industries Ltd. - Product / Service; Sun Pharmaceutical Industries Ltd. - Key news; Sun Pharmaceutical Industries Ltd. - Key offerings; 12.16 Theratechnologies Inc.; Theratechnologies Inc. - Overview; Theratechnologies Inc. - Product / Service; Theratechnologies Inc. - Key offerings; 12.17 Viatris Inc.; Viatris Inc. - Overview; Viatris Inc. - Business segments; Viatris Inc. - Key news; Viatris Inc. - Key offerings; Viatris Inc. - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 13.3 Currency conversion rates for US$; Currency conversion rates for US$; 13.4 Research methodology; Research methodology; 13.5 Data procurement; Information sources; 13.6 Data validation; Data validation; 13.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 13.8 Data synthesis; Data synthesis; 13.9 360 degree market analysis; 360 degree market analysis; 13.10 List of abbreviations; List of abbreviations; Exhibits:; Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibits6: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Company Market Positioning; Exhibits10: Parent Market; Exhibits11: Data Table on - Parent Market; Exhibits12: Market characteristics analysis; Exhibits13: Value Chain Analysis; Exhibits14: Offerings of companies included in the market definition; Exhibits15: Market segments; Exhibits16: Chart on Africa - Market size and forecast 2023-2028 ($ million); Exhibits17: Data Table on Regional - Market size and forecast 2023-2028 ($ million); Exhibits18: Chart on Africa: Year-over-year growth 2023-2028 (%); Exhibits19: Data Table on Regional - Market size and forecast 2023-2028 ($ million); Exhibits20: Historic Market Size - Data Table on HIV Treatment Drugs Market in Africa 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million); Exhibits23: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits24: Five forces analysis - Comparison between 2023 and 2028; Exhibits25: Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits26: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits27: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits28: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits29: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits30: Chart on Market condition - Five forces 2023 and 2028; Exhibits31: Chart on Drug Class - Market share 2023-2028 (%); Exhibits32: Data Table on Drug Class - Market share 2023-2028 (%); Exhibits33: Chart on Comparison by Drug Class; Exhibits34: Data Table on Comparison by Drug Class; Exhibits35: Chart on Reverse transcriptase inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits36: Data Table on Reverse transcriptase inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits37: Chart on Reverse transcriptase inhibitors - Year-over-year growth 2023-2028 (%); Exhibits38: Data Table on Reverse transcriptase inhibitors - Year-over-year growth 2023-2028 (%); Exhibits39: Chart on Protease inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits40: Data Table on Protease inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits41: Chart on Protease inhibitors - Year-over-year growth 2023-2028 (%); Exhibits42: Data Table on Protease inhibitors - Year-over-year growth 2023-2028 (%); Exhibits43: Chart on Integrase inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits44: Data Table on Integrase inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits45: Chart on Integrase inhibitors - Year-over-year growth 2023-2028 (%); Exhibits46: Data Table on Integrase inhibitors - Year-over-year growth 2023-2028 (%); Exhibits47: Chart on Fusion inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits48: Data Table on Fusion inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits49: Chart on Fusion inhibitors - Year-over-year growth 2023-2028 (%); Exhibits50: Data Table on Fusion inhibitors - Year-over-year growth 2023-2028 (%); Exhibits51: Chart on Coreceptor antagonists - Market size and forecast 2023-2028 ($ million); Exhibits52: Data Table on Coreceptor antagonists - Market size and forecast 2023-2028 ($ million); Exhibits53: Chart on Coreceptor antagonists - Year-over-year growth 2023-2028 (%); Exhibits54: Data Table on Coreceptor antagonists - Year-over-year growth 2023-2028 (%); Exhibits55: Market opportunity by Drug Class ($ million); Exhibits56: Data Table on Market opportunity by Drug Class ($ million); Exhibits57: Chart on Route of Administration - Market share 2023-2028 (%); Exhibits58: Data Table on Route of Administration - Market share 2023-2028 (%); Exhibits59: Chart on Comparison by Route of Administration; Exhibits60: Data Table on Comparison by Route of Administration; Exhibits61: Chart on Oral drugs - Market size and forecast 2023-2028 ($ million); Exhibits62: Data Table on Oral drugs - Market size and forecast 2023-2028 ($ million); Exhibits63: Chart on Oral drugs - Year-over-year growth 2023-2028 (%); Exhibits64: Data Table on Oral drugs - Year-over-year growth 2023-2028 (%); Exhibits65: Chart on Injectable drugs - Market size and forecast 2023-2028 ($ million); Exhibits66: Data Table on Injectable drugs - Market size and forecast 2023-2028 ($ million); Exhibits67: Chart on Injectable drugs - Year-over-year growth 2023-2028 (%); Exhibits68: Data Table on Injectable drugs - Year-over-year growth 2023-2028 (%); Exhibits69: Market opportunity by Route of Administration ($ million); Exhibits70: Data Table on Market opportunity by Route of Administration ($ million); Exhibits71: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits72: Chart on Market share By Geographical Landscape - 2023-2028 (%); Exhibits73: Data Table on Market share By Geographical Landscape - 2023-2028 (%); Exhibits74: Chart on Geographic comparison; Exhibits75: Data Table on Geographic comparison; Exhibits76: Chart on South Africa - Market size and forecast 2023-2028 ($ million); Exhibits77: Data Table on South Africa - Market size and forecast 2023-2028 ($ million); Exhibits78: Chart on South Africa - Year-over-year growth 2023-2028 (%); Exhibits79: Data Table on South Africa - Year-over-year growth 2023-2028 (%); Exhibits80: Chart on Nigeria - Market size and forecast 2023-2028 ($ million); Exhibits81: Data Table on Nigeria - Market size and forecast 2023-2028 ($ million); Exhibits82: Chart on Nigeria - Year-over-year growth 2023-2028 (%); Exhibits83: Data Table on Nigeria - Year-over-year growth 2023-2028 (%); Exhibits84: Chart on Kenya - Market size and forecast 2023-2028 ($ million); Exhibits85: Data Table on Kenya - Market size and forecast 2023-2028 ($ million); Exhibits86: Chart on Kenya - Year-over-year growth 2023-2028 (%); Exhibits87: Data Table on Kenya - Year-over-year growth 2023-2028 (%); Exhibits88: Chart on Uganda - Market size and forecast 2023-2028 ($ million); Exhibits89: Data Table on Uganda - Market size and forecast 2023-2028 ($ million); Exhibits90: Chart on Uganda - Year-over-year growth 2023-2028 (%); Exhibits91: Data Table on Uganda - Year-over-year growth 2023-2028 (%); Exhibits92: Chart on Rest of Africa - Market size and forecast 2023-2028 ($ million); Exhibits93: Data Table on Rest of Africa - Market size and forecast 2023-2028 ($ million); Exhibits94: Chart on Rest of Africa - Year-over-year growth 2023-2028 (%); Exhibits95: Data Table on Rest of Africa - Year-over-year growth 2023-2028 (%); Exhibits96: Market opportunity By Geographical Landscape ($ million); Exhibits97: Data Table on Market opportunity By Geographical Landscape ($ million); Exhibits98: Impact of drivers and challenges in 2023 and 2028; Exhibits99: Overview on criticality of inputs and factors of differentiation; Exhibits100: Overview on factors of disruption; Exhibits101: Impact of key risks on business; Exhibits102: Companies covered; Exhibits103: Matrix on companies position and classification; Exhibits104: Abbott Laboratories - Overview; Exhibits105: Abbott Laboratories - Business segments; Exhibits106: Abbott Laboratories - Key news; Exhibits107: Abbott Laboratories - Key offerings; Exhibits108: Abbott Laboratories - Segment focus; Exhibits109: AbbVie Inc. - Overview; Exhibits110: AbbVie Inc. - Product / Service; Exhibits111: AbbVie Inc. - Key news; Exhibits112: AbbVie Inc. - Key offerings; Exhibits113: Alpha Pharma - Overview; Exhibits114: Alpha Pharma - Product / Service; Exhibits115: Alpha Pharma - Key offerings; Exhibits116: Aspen Pharmacare Holdings Ltd. - Overview; Exhibits117: Aspen Pharmacare Holdings Ltd. - Business segments; Exhibits118: Aspen Pharmacare Holdings Ltd. - Key offerings; Exhibits119: Aspen Pharmacare Holdings Ltd. - Segment focus; Exhibits120: AstraZeneca Plc - Overview; Exhibits121: AstraZeneca Plc - Product / Service; Exhibits122: AstraZeneca Plc - Key news; Exhibits123: AstraZeneca Plc - Key offerings; Exhibits124: Aurobindo Pharma Ltd. - Overview; Exhibits125: Aurobindo Pharma Ltd. - Product / Service; Exhibits126: Aurobindo Pharma Ltd. - Key offerings; Exhibits127: Avacare Health - Overview; Exhibits128: Avacare Health - Product / Service; Exhibits129: Avacare Health - Key offerings; Exhibits130: Cipla Inc. - Overview; Exhibits131: Cipla Inc. - Business segments; Exhibits132: Cipla Inc. - Key news; Exhibits133: Cipla Inc. - Key offerings; Exhibits134: Cipla Inc. - Segment focus; Exhibits135: F. Hoffmann La Roche Ltd. - Overview; Exhibits136: F. Hoffmann La Roche Ltd. - Business segments; Exhibits137: F. Hoffmann La Roche Ltd. - Key news; Exhibits138: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits139: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits140: Gilead Sciences Inc. - Overview; Exhibits141: Gilead Sciences Inc. - Product / Service; Exhibits142: Gilead Sciences Inc. - Key news; Exhibits143: Gilead Sciences Inc. - Key offerings; Exhibits144: GlaxoSmithKline Plc - Overview; Exhibits145: GlaxoSmithKline Plc - Business segments; Exhibits146: GlaxoSmithKline Plc - Key news; Exhibits147: GlaxoSmithKline Plc - Key offerings; Exhibits148: GlaxoSmithKline Plc - Segment focus; Exhibits149: Merck and Co. Inc. - Overview; Exhibits150: Merck and Co. Inc. - Business segments; Exhibits151: Merck and Co. Inc. - Key news; Exhibits152: Merck and Co. Inc. - Key offerings; Exhibits153: Merck and Co. Inc. - Segment focus; Exhibits154: Sun Pharmaceutical Industries Ltd. - Overview; Exhibits155: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibits156: Sun Pharmaceutical Industries Ltd. - Key news; Exhibits157: Sun Pharmaceutical Industries Ltd. - Key offerings; Exhibits158: Theratechnologies Inc. - Overview; Exhibits159: Theratechnologies Inc. - Product / Service; Exhibits160: Theratechnologies Inc. - Key offerings; Exhibits161: Viatris Inc. - Overview; Exhibits162: Viatris Inc. - Business segments; Exhibits163: Viatris Inc. - Key news; Exhibits164: Viatris Inc. - Key offerings; Exhibits165: Viatris Inc. - Segment focus; Exhibits166: Inclusions checklist; Exhibits167: Exclusions checklist; Exhibits168: Currency conversion rates for US$; Exhibits169: Research methodology; Exhibits170: Information sources; Exhibits171: Data validation; Exhibits172: Validation techniques employed for market sizing; Exhibits173: Data synthesis; Exhibits174: 360 degree market analysis; Exhibits175: List of abbreviations